男受被做哭激烈娇喘gv视频,成人片免费网站,今天高清视频免费播放作文,欧美大片ppt免费

一項薈萃分析研究數據顯示，使用他汀類致新發糖尿病風險增加會因劑量和藥物類型而有差異。研究結果1月25日在線發表于《美國心臟病學雜志》(The American Journal of Cardiology)。

與安慰劑相比，普伐他汀40 mg/d致糖尿病的風險最低(比值比1.07)。風險最高的是瑞舒伐他汀40 mg/d(比值比1.25)。中等風險的是阿托伐他汀80 mg/d(比值比1.15)。

與中等劑量方案相比，劑量較大方案致糖尿病風險普遍增加。例如，瑞舒伐他汀20 mg/d的相對風險比10 mg/d高12%。

牽頭進行該研究的Eliano P. Navarese博士表示，這項薈萃分析首次明確顯示“致糖尿病風險與他汀類的不同劑量及類型存在梯度相關。”

波蘭彼得哥什市哥白尼大學的Navarese博士和同事研究了包括11.3萬多名受試者的17項隨機對照試驗的數據，這些試驗比較了他汀類與安慰劑或不同劑量的他汀類治療結果。隨訪范圍為2~6年。

在臨床意義方面，Navarese博士指出，“如果這項網絡薈萃分析的結果能夠在效能足夠的頭對頭比較中被證實，那將對全球數百萬接受他汀類治療的患者的管理具有重要意義。一種新的他汀類治療方案可能會出現，那時個體化他汀類治療有可能成為最安全有效的治療策略。”

Meta-Analysis of Impact of Different Types and Doses of Statins on New-Onset Diabetes Mellitus.

Recent reports indicate that statins are associated with an increased risk for new-onset diabetes mellitus (DM) compared with placebo and that this relation is dose dependent. The aim of this study was to perform a comprehensive network meta-analysis of randomized controlled trials (RCTs) investigating the impact of different types and doses of statins on new-onset DM. RCTs comparing different types and doses of statins with placebo were searched for using the MEDLINE, Embase, and Cochrane databases. A search of RCTs pertinent to this meta-analysis covering the period from November 1994 to October 2012 was conducted by 2 independent investigators using the MEDLINE, Cochrane, Google Scholar, and Embase databases as well as abstracts and presentations from major cardiovascular meetings. Seventeen RCTs reporting the incidence of new-onset DM during statin treatment and including a total of 113,394 patients were identified. The RCTs compared either a statin versus placebo or high-dose versus moderate-dose statin therapy. Among different statins, pravastatin 40 mg/day was associated with the lowest risk for new-onset DM compared with placebo (odds ratio 1.07, 95% credible interval 0.86 to 1.30). Conversely, rosuvastatin 20 mg/day was numerically associated with 25% increased risk for DM compared with placebo (odds ratio 1.25, 95% credible interval 0.82 to 1.90). The impact on DM appeared to be intermediate with atorvastatin 80 mg/day compared with placebo (odds ratio 1.15, 95% credible interval 0.90 to 1.50). These findings were replicated at moderate doses. In conclusion, different types and doses of statins show different potential to increase the incidence of DM.